Find Droxidopa manufacturers, exporters & distributors on PharmaCompass

Northera

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

21 API Suppliers, 10 USDMF, 5 JDMF, 2 EU WC, 1 KDMF, 8 NDC API, 10 Listed Suppliers

21 API Suppliers
10 USDMF
5 JDMF
2 EU WC
1 KDMF
8 NDC API
10 Listed Suppliers

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

57 FDF Dossiers, 51 FDA Orange Book, 3 Europe, 3 Listed Dossiers

57 FDF Dossiers
51 FDA Orange Book
3 Europe
3 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 15 SPI Pharma, 7 DKSH, 3 Faran Shimi Pharmaceutical, 6 Gangwal Healthcare, 1 Pfanstiehl, 4 ACG Worldwide, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 3 Gangwal Chemicals, 3 Ingredion Pharma Solutions, 3 Kerry, 3 Lonza Capsugel, 7 Microlex e.U, 3 Pluviaendo, 1 Prachin Chemical, 1 Qualicaps, 10 Roquette, 1 Seppic, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

40 Fillers, Diluents & Binders, 18 Direct Compression, 13 Chewable & Orodispersible Aids, 13 Taste Masking, 10 Co-Processed Excipients, 8 Empty Capsules, 8 Lubricants & Glidants, 8 Thickeners and Stabilizers, 7 Disintegrants & Superdisintegrants, 6 Coating Systems & Additives, 4 Parenteral, 4 Granulation, 3 Coloring Agents, 2 Film Formers & Plasticizers, 2 Controlled & Modified Release, 1 API Stability Enhancers, 1 Emulsifying Agents

excipientsByApplications
40 Fillers, Diluents & Binders
18 Direct Compression
13 Chewable & Orodispersible Aids
13 Taste Masking
10 Co-Processed Excipients
8 Empty Capsules
8 Lubricants & Glidants
8 Thickeners and Stabilizers
7 Disintegrants & Superdisintegrants
6 Coating Systems & Additives
4 Parenteral
4 Granulation
3 Coloring Agents
2 Film Formers & Plasticizers
2 Controlled & Modified Release
1 API Stability Enhancers
1 Emulsifying Agents

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 7 NEWS #PharmaBuzz

media
3 DATA COMPILATION #PharmaFlow
7 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 6 Annual Reports

globalSalesInformation
2 US Medicaid Prescriptions
6 Annual Reports

MARKET PLACE

3 APIs

marketPlace
3 APIs

REF. STANDARDS & IMPURITIES

1 Others

otherSolutions
1 Others

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

5INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

105,716,036

Annual Reports (USD Million)

1,419

Finished Drug Prices

81 RELATED EXCIPIENT COMPANIES

148EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 23651-95-8, L-dops, Dops, Northera, 3916-18-5, (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid

Molecular Formula

C₉H₁₁NO₅

Molecular Weight

213.19 g/mol

InChI Key

QXWYKJLNLSIPIN-JGVFFNPUSA-N

FDA UNII

24A0V01WKS

A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.

The physiologic effect of droxidopa is by means of Increased Blood Pressure.

1 2D Structure

Droxidopa

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid

2.1.2 InChI

InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1

2.1.3 InChI Key

QXWYKJLNLSIPIN-JGVFFNPUSA-N

2.1.4 Canonical SMILES

C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O

2.1.5 Isomeric SMILES

C1=CC(=C(C=C1[C@H]([C@@H](C(=O)O)N)O)O)O

2.2 Other Identifiers

2.2.1 UNII

24A0V01WKS

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 3,4 Dihydroxyphenylserine

2. 3,4 Threo Dops

3. 3,4-dihydroxyphenylserine

4. 3,4-threo-dops

5. Dl Threo 3,4 Dihydroxyphenylserine

6. Dl-threo-3,4-dihydroxyphenylserine

7. Droxidopa, (dl-tyr)-isomer

8. Erythro 3,4 Dihydroxyphenylserine

9. Erythro-3,4-dihydroxyphenylserine

10. Threo Dops

11. Threo-dops

2.3.2 Depositor-Supplied Synonyms

1. 23651-95-8

2. L-dops

3. Dops

4. Northera

5. 3916-18-5

6. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid

7. Dl-threo-droxidopa

8. Dl-threo-3,4-dihydroxyphenylserine

9. Dl-threo-dops

10. Threo-dopaserine

11. L-threodops

12. L-threo-dops

13. Dl-threo-dihydroxyphenylserine

14. Threo-dihydroxyphenylserine

15. Sm 5688

16. Chebi:31524

17. L-dihydroxyphenylserine

18. Droxidopa (l-dops)

19. Serine, 3-(3,4-dihydroxyphenyl)-, Dl-threo-

20. L-threo-dihydroxyphenylserine

21. 24a0v01wks

22. J7a92w69l7

23. Dl-threo-beta-(3,4-dihydroxyphenyl)serine

24. Droxydopa

25. L-threo-3,4-dihydroxyphenylserine

26. Norethra

27. Droxidopa [latin]

28. Threo-beta,3-dihydroxy-dl-tyrosine

29. Einecs 223-480-5

30. Beta,3-dihydroxy-dl-tyrosine Threo-

31. 3,4-dihydroxyphenylserine

32. Brn 2852792

33. Droxidopum

34. L-tyrosine, Beta,3-dihydroxy-, Threo-

35. Unii-24a0v01wks

36. Dl-threo-3-(3,4-dihydroxyphenyl)serine

37. Droxidopa [usan:inn:jan]

38. Unii-j7a92w69l7

39. (2rs,3rs)-2-amino-3-(3,4-dihydroxy-phenyl)-3-hydroxy-propionic Acid

40. L-threo 3,4-dihydroxyphenylserine

41. Northera (tn)

42. L-threo Dops

43. Dops (tn)

44. L-threo-3-(3,4-dihydroxyphenyl)serine

45. Dl-tyrosine, Beta,3-dihydroxy-, Threo-

46. Droxidopa [inn]

47. Droxidopa [jan]

48. Droxidopa [mi]

49. Threo-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid

50. Droxidopa [usan]

51. Dl-tyrosine, .beta.,3-dihydroxy-, Threo-

52. Droxidopa [vandf]

53. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic Acid

54. Droxidopa [mart.]

55. Droxidopa [who-dd]

56. 1-14-00-00685 (beilstein Handbook Reference)

57. 1260173-94-1

58. Schembl134299

59. Gtpl7391

60. Droxidopa (jp17/usan/inn)

61. Droxidopa [orange Book]

62. Chembl2103827

63. Dtxsid6046422

64. Droxidopa (l-dops,sm-5688)

65. Dtxsid201017236

66. Bcp06516

67. Zinc1482049

68. Bdbm50103611

69. Mfcd00799030

70. S3041

71. Sm5688

72. (betar)-beta,3-dihydroxy-l-tyrosine

73. L-dops, >=98% (hplc)

74. (2s,3r)-3,4-dihydroxy-phenylserine

75. Akos015889899

76. Ccg-222060

77. Db06262

78. Sm-5688

79. Ncgc00344531-04

80. As-61328

81. Hy-13458

82. L-tyrosine, Beta,3-dihydroxy-, (betar)-

83. D4235

84. L-tyrosine, Beta,3-dihydroxy-, (beta-r)-

85. Threo-3,4-dihydroxyphenylserine, L-

86. 3,4-dihydroxyphenylserine-threo, Dl-

87. Dl-threo- Beta -(3,4-dihydroxyphenyl)serine

88. (-)-threo-3-(3,4-dihydroxyphenyl)-l-serine

89. D01277

90. D90266

91. Serine, 3-(3,4-dihydroxyphenyl)-, L-threo-

92. Ab01566868_01

93. 916a185

94. A816824

95. Q907853

96. Sr-01000883755

97. Q-201050

98. Sr-01000883755-1

99. L-tyrosine, .beta.,3-dihydroxy-, (.beta.r)-

100. D-tyrosine, .beta.,3-dihydroxy-, (.beta.s)-rel-

101. 23651-95-8,1260173-94-1(hcl)

102. (2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropionic Acid

103. (2s,3r)-3-(3,4-dihydroxyphenyl)-2-amino-3-hydroxypropanoic Acid

104. (-)-(2s,3r)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propanoic Acid

105. (2rs,3rs)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxy-propanoic Acid

106. (-)-(2s,3r)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic Acid

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₉H₁₁NO₅
Molecular Weight	213.19 g/mol
XLogP3	-3.2
Hydrogen Bond Donor Count	5
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Exact Mass	213.06372245 g/mol
Monoisotopic Mass	213.06372245 g/mol
Topological Polar Surface Area	124 Å²
Heavy Atom Count	15
Formal Charge	0
Complexity	235
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Northera
PubMed Health	Droxidopa (Oral route)
Drug Classes	Adrenergic, Vasopressor
Drug Label	NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is...
Active Ingredient	Droxidopa
Dosage Form	Capsule
Route	Oral
Strength	200mg; 300mg; 100mg
Market Status	Prescription
Company	Lundbeck Na

2 of 2
Drug Name	Northera
PubMed Health	Droxidopa (Oral route)
Drug Classes	Adrenergic, Vasopressor
Drug Label	NORTHERA capsules contain droxidopa, which is a synthetic amino acid precursor of norepinephrine, for oral administration. Chemically, droxidopa is ()-threo-3-(3,4-Dihydroxyphenyl)-L-serine. It has the following structural formula:Droxidopa is...
Active Ingredient	Droxidopa
Dosage Form	Capsule
Route	Oral
Strength	200mg; 300mg; 100mg
Market Status	Prescription
Company	Lundbeck Na

4.2 Drug Indication

For treatment of neurogenic orthostatic hypotension (NOH) associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.

5 Pharmacology and Biochemistry

5.1 Pharmacology

Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.

5.2 MeSH Pharmacological Classification

Antiparkinson Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

DROXIDOPA

5.3.2 FDA UNII

J7A92W69L7

5.3.3 Pharmacological Classes

Increased Blood Pressure [PE]; Catecholamines [CS]

5.4 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01C - Cardiac stimulants excl. cardiac glycosides

C01CA - Adrenergic and dopaminergic agents

C01CA27 - Droxidopa

5.5 Absorption, Distribution and Excretion

Absorption

Oral bioavailability is 90%.

Route of Elimination

Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.

5.6 Metabolism/Metabolites

Droxidopa is metabolized by aromatic L-amino acid decarboxylase.

5.7 Biological Half-Life

2-3 hours.

5.8 Mechanism of Action

Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.

API SUPPLIERS